<DOC>
	<DOCNO>NCT02691871</DOCNO>
	<brief_summary>The purpose study confirm safety Apatinib dose level 750 mg/d standard therapy docetaxel ( 60 mg/m² ) advance lung adenocarcinoma patient harbor wild-type EGFR failure first line chemotherapy determine recommend dose Phase II trial .</brief_summary>
	<brief_title>Apatinib Plus Docetaxel 2nd Line Treatment Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . 18 year 65 year ; 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; 3 . Life expectancy 12 week ; 4 . At least one measurable lesion accord RECIST 1.1 receive radiotherapy = &lt; 3 month ; 5 . Histologically/cytologically confirm advanced/metastatic lung adenocarcinoma stage IV document wildtype EGFR ; 6 . Patients one prior platinumcontaining chemotherapy . In case recurrent disease , one additional prior regimen allow adjuvant and/or neoadjuvant therapy . 7 . Adequate hepatic , renal , heart , hematologic function : ANC ≥ 1.5×109/L , PLT ≥ 100×109/L , HB ≥ 90 g/L , TBIL ≤ 1.5×ULN , ALT AST ≤ 2.5×ULN ( ≤ 5×ULN patient liver metastasis ) , Serum Cr ≤ 1×ULN , Cr clearance ≥ 50 mL/min , INR &lt; 1.5 PT &lt; ULN+4s APTT &lt; 1.5×ULN , proteinuria &lt; ( ++ ) urinary protein ≤ 1.0 g/24 hr ; 8 . For woman childbearing age , pregnancy test result ( serum urine ) within 7 day enrolment must negative . They take appropriate method contraception study 8th week post last administration study drug . For men ( previous surgical sterilization accept ) , take appropriate method contraception study 8th week post last administration study drug . 9 . Signed informed consent . 1 . Accumulation coelomic fluid ( e.g . pleural effusion , ascites fluid , cardiac effusion ) require treatment ; 2 . Other malignancy within past five year basal cell skin cancer , carcinoma situ cervix ; 3 . Factors affect oral medication ( e.g . inability swallow , chronic diarrhea intestinal obstruction ) ; 4 . Major injury and/or surgery = &lt; 4 week prior registration incomplete wound heal . Patients receive radiotherapy ( except local palliative radiotherapy ) , chemotherapy , molecular target therapy = &lt; 3 week , nitrosoureas/mitomycin chemotherapy = &lt; 6 week prior registration ; 5 . Patients poorcontrolled arterial hypertension ( systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mm Hg ) despite standard medical management ; 6 . Suffered grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia ( include QT interval male ≥ 450 m , female ≥ 470 m ) . Grade IIIIV cardiac insufficiency accord NYHA criterion echocardiography check : LVEF &lt; 50 % ; 7 . History clinically significant haemoptysis = &lt; 2 month ( half one tea spoon fresh blood per day ) prior registration . Coagulation disfunction , hemorrhagic tendency receive anticoagulant therapy ; 8 . History clinically relevant major bleed event ( e.g . gastrointestinal hemorrhage , bleed ulcer , occult blood ≥ ( ++ ) , vasculitis ) = &lt; 3 month prior randomization ; 9 . Patients active brain metastasis leptomeningeal disease . Patients treat brain metastasis eligible clinically stable regard neurologic function , steroid cranial irradiation end least 3 week prior randomization , surgical resection perform least 3 week prior randomization . No evidence Grade great equal 1 CNS hemorrhage base pretreatment CT MRI scan ; 10 . Centrally locate tumor local invasion major blood vessel , distinct interstitial lung disease chest radiographic finding ( CT MRI ) ; 11 . Treatment investigational drug anticancer therapy ; 12 . Previous therapy VEGFR inhibitor ( bevacizumab ) ; 13 . Previous therapy docetaxel = &lt; 6 month prior registration ; 14 . Treatment another investigational trial = &lt; 4 week prior registration ; 15 . Any contraindication therapy docetaxel . History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 ( Tween 80 ) . History hypersensitivity apatinib and/or excipients trial drug ; 16 . Active chronic hepatitis C and/or B infection , active uncontrolled infection ; 17 . History immunodeficiency disease ( include HIV positive ) , concurrent acquire congenital immunodeficiency syndrome , history organ transplantation ; 18 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess = &lt; 6 month prior registration ; 19 . History arterial venous thromboembolic event ( e.g . CVA , DVT pulmonary embolism ) = &lt; 12 month prior randomization ; 20 . Administration strong/potent cytochrome P450 ( CYP ) 3A4 inhibitor within 7 day , inducer within 12 day ; 21 . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study ; 22 . History mental disease ; 23 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>